Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.

Trial therapy for lymphoma with the radiolabeled chelate-antibody conjugate 67Cu-2IT-BAT-Lym-1 has been promising. It is desirable to deliver therapeutic doses of radiometal using a minimum amount of 2IT-BAT-Lym-1 to minimize the risks of adverse patient reaction and antigenic response to antibody. This is readily accomplished by increasing the number of metal-binding sites (i.e., chelating agents) conjugated per antibody, but the ability of the antibody to bind antigen and target tumor cells in vivo must not be impaired by the conjugation reaction. To determine the maximum chelator:antibody ratio (c/a) of 2IT-BAT-Lym-1 at which functional integrity is preserved, immunoconjugates with a c/a of 1.3-23 were prepared and examined by radioimmunoassay and competitive antigen binding versus lightly iodinated Lym-1. The biodistribution in tumored mice of conjugates with c/a of 2.1, 4.3, 8.4, and 11.4 also was examined. Conjugates with c/a up to 5 exhibited no loss of immunoreactivity, and conjugates with c/a up to 11 retained 75% or greater immunoreactivity relative to unmodified Lym-1. All conjugates examined competed less effectively than did unmodified Lym-1 for antigen binding, but the effect at c/a 5 was slight. Tumor uptake declined with increasing c/a, but the effect was insignificant at c/a 2.1 and 4.3. Conjugates of c/a 4-5 were found to be optimal for the preparation of radioimmunoconjugate of high specific activity with minimal, if any, loss of functional integrity.

[1]  G. Meinken,et al.  Improved production, and evaluation of Cu-67 for tumor radioimmunotherapy , 1994 .

[2]  G. Denardo,et al.  A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates , 1994, Cancer.

[3]  G. Denardo,et al.  Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3) , 1994, Cancer.

[4]  M. Gerretsen,et al.  Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  D. Kukis,et al.  Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals , 1993 .

[6]  V. Torchilin,et al.  Biodistribution of anti-CEA F(ab')2 fragments conjugated with chelating polymers: influence of conjugate electron charge on tumor uptake and blood clearance. , 1993, Nuclear medicine and biology.

[7]  S. Houle,et al.  In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[8]  M. Hanna,et al.  New chelating agent for attaching indium-111 to monoclonal antibodies: in vitro and in vivo evaluation. , 1992, Bioconjugate chemistry.

[9]  S. Rosen,et al.  Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. , 1991, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[10]  M. Welch,et al.  N,N'-bis(2-hydroxybenzyl)-1-(4-bromoacetamidobenzyl)-1,2 -ethylenediamine-N,N'-diacetic acid: a new bifunctional chelate for radiolabeling antibodies. , 1990, Bioconjugate chemistry.

[11]  T. Rana,et al.  N-terminal modification of immunoglobulin polypeptide chains tagged with isothiocyanato chelates. , 1990, Bioconjugate chemistry.

[12]  V. Torchilin,et al.  Succinylated polylysine as a possible link between an antibody molecule and deferoxamine. , 1990, Bioconjugate chemistry.

[13]  C. Meares,et al.  Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. , 1990, Bioconjugate chemistry.

[14]  H. P. Fell,et al.  Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal anticarcinoma antibody. , 1990, Cancer research.

[15]  S. Larson,et al.  Immunoreactivity affects the biodistribution and tumor targeting of radiolabeled anti-P97 Fab fragment. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  G. Denardo,et al.  Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. , 1990, Cancer research.

[17]  S. Stroupe,et al.  An optimized antibody-chelator conjugate for imaging of carcinoembryonic antigen with indium-111. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[18]  M. Eaton,et al.  Towards tumour targeting with copper-radiolabelled macrocycle–antibody conjugates , 1989 .

[19]  J. C. Roberts,et al.  The biodistribution of radiocopper-labeled compounds. , 1989, Advances in experimental medicine and biology.

[20]  J. C. Roberts,et al.  Labeling antibodies with copper radionuclides using N-4-nitrobenzyl-5-(4-carboxyphenyl)-10,15,20-tris(4-sulfophenyl) porphine. , 1989, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[21]  G. Denardo,et al.  Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  S. Denardo,et al.  Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. , 1985, Analytical biochemistry.

[23]  A. M. Zimmer,et al.  Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1) , 1985 .

[24]  R. Reba,et al.  Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  H. Penefsky.  A centrifuged-column procedure for the measurement of ligand binding by beef heart F1. , 1979, Methods in enzymology.

[26]  D. Burk,et al.  The Determination of Enzyme Dissociation Constants , 1934 .